Major French study confirms non-inferiority of Avastin versus Lucentis
A multicentre French study comparing bevacizumab (Avastin, Genentech) and ranibizumab (Lucentis, Genentech) found that both drugs were comparable in terms of clinical efficacy for the treatment of neovascular age-related macular degeneration (AMD).
Presenting the results of the Group d’Evaluation Français Avastin versus Lucentis (GEFAL) study at the 13th EURETINA Congress, Laurent Kodjikian MD of the University Hospital of Lyon, said that the outcomes are in line with those of the Comparison of AMD Treatment Trial (CATT) published in 2012.
The GEFAL study was a prospective, double-masked, randomised study conducted in 38 public and private-sector French ophthalmology centres from June 2009 to November 2011.
Latest Articles
Towards a Unified IOL Classification
The new IOL functional classification needs a strong and unified effort from surgeons, societies, and industry.
The 5 Ws of Post-Presbyopic IOL Enhancement
Fine-tuning refractive outcomes to meet patient expectations.
AI Shows Promise for Meibography Grading
Study demonstrates accuracy in detecting abnormalities and subtle changes in meibomian glands.
Are There Differences Between Male and Female Eyes?
TOGA Session panel underlined the need for more studies on gender differences.
Simulating Laser Vision Correction Outcomes
Individualised planning models could reduce ectasia risk and improve outcomes.
Need to Know: Aberrations, Aberrometry, and Aberropia
Understanding the nomenclature and techniques.
When Is It Time to Remove a Phakic IOL?
Close monitoring of endothelial cell loss in phakic IOL patients and timely explantation may avoid surgical complications.
Delivering Uncompromising Cataract Care
Expert panel considers tips and tricks for cataracts and compromised corneas.
Organising for Success
Professional and personal goals drive practice ownership and operational choices.